The risks and benefits of HPV vaccination.
Haug
Charlotte
C
D016907:Adverse Drug Reaction Reporting Systems; D040861:Ethics, Business; D005260:Female; D005378:Financial Support; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D006801:Humans; D040541:Marketing; D030361:Papillomavirus Infections / Q000517:prevention & control; D053918:Papillomavirus Vaccines / Q000009:adverse effects; D018570:Risk Assessment; D014481:United States; D002583:Uterine Cervical Neoplasms / Q000517:prevention & control / Q000821:virology; D014611:Vaccination / Q000592:standards
D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D053918:Papillomavirus Vaccines